CoChat

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology

Open access
Carvalho, Cláudia, Lemos, Luísa, Antas, Pedro, Seabra, Miguel C. · 2023 · Frontiers in Ophthalmology

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

Inherited retinal diseases (IRDs) encompass a diverse group of genetic disorders that lead to progressive visual impairment and blindness. Over the years, considerable strides have been made in understanding the underlying molecular mechanisms of IRDs, laying the foundation for novel therapeutic interventions. Gene therapy has emerged as a compelling approach for treating IRDs, with notable advancements achieved through targeted gene augmentation. However, several setbacks and limitations persist, hindering the widespread clinical success of gene therapy for IRDs. One promising avenue of research is the development of new genome editing tools. Cutting-edge technologies such as CRISPR-Cas9 nucleases, base editing and prime editing provide unprecedented precision and efficiency in targeted gene manipulation, offering the potential to overcome existing challenges in gene therapy for IRDs. Furthermore, traditional gene therapy encounters a significant challenge due to immune responses to viral vectors, which remain crucial obstacles in achieving long-lasting therapeutic effects. Nanotechnology has emerged as a valuable ally in the quest to optimize gene therapy outcomes for ocular diseases. Nanoparticles engineered with nanoscale precision offer improved gene delivery to specific retinal cells, allowing for enhanced targeting and reduced immunogenicity. In this review, we discuss recent advancements in gene therapy for IRDs and explore the setbacks that have been encountered in clinical trials. We highlight the technological advances in genome editing for the treatment of IRDs and how integrating nanotechnology into gene delivery strategies could enhance the safety and efficacy of gene therapy, ultimately offering hope for patients with IRDs and potentially paving the way for similar advancements in other ocular disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fopht.2023.1270561

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Comparison of CRISPR/Cas9 nucleases, base editors, and prime editors. This figure provides an overview of the components and mechanisms of action of CRISPR/Cas9 nucleases, base editors, and prime editors, highlighting their unique abilities in achieving specific genetic modifications with varying levels of precision. CRISPR/Cas9 is a powerful genome editing tool that uses a guide RNA (gRNA) to target specific DNA sequences within the genome. The Cas9 enzyme acts as molecular scissors, creating double-strand breaks (DSBs) at the targeted site. This prompts the cell’s natural repair machinery to introduce insertions or deletions by non-homologous end-joining (NHEJ), resulting in gene disruption or knockout. In the presence of a donor DNA (dDNA) template, DSBs can alternatively be corrected by homology-directed repair (HDR), provided that the cell is in the G2 or S phases of the cell cycle. Base editors are genome editing tools designed to introduce precise single-nucleotide mutations without causing DSBs. They utilize a modified Cas9 enzyme fused to a deaminase enzyme to convert a targeted DNA base pair (e.g., A•T to I•T) without disrupting the DNA backbone. Subsequently, the cell’s repair machinery converts the modified base into a desired substitution. Prime editing is a gene editing technique that allows the precise insertion, deletion, or substitution of DNA sequences at target sites, without requiring DSBs. Prime editors consist of a catalytically impaired Cas9 fused to an engineered reverse transcriptase and a prime editing guide RNA (pegRNA). The pegRNA directs the reverse transcriptase (RT) to introduce the desired edito into the target DNA. PBS: primer binding site, RTT: reverse transcription template.
Figure 1 Comparison of CRISPR/Cas9 nucleases, base editors, and prime editors. This figure provides an overview of the components and mechanisms of action of CRISPR/Cas9 nucleases, base editors, and prime editors, highlighting their unique abilities in achieving specific genetic modifications with varying levels of precision. CRISPR/Cas9 is a powerful genome editing tool that uses a guide RNA (gRNA) to target specific DNA sequences within the genome. The Cas9 enzyme acts as molecular scissors, creating double-strand breaks (DSBs) at the targeted site. This prompts the cell’s natural repair machinery to introduce insertions or deletions by non-homologous end-joining (NHEJ), resulting in gene disruption or knockout. In the presence of a donor DNA (dDNA) template, DSBs can alternatively be corrected by homology-directed repair (HDR), provided that the cell is in the G2 or S phases of the cell cycle. Base editors are genome editing tools designed to introduce precise single-nucleotide mutations without causing DSBs. They utilize a modified Cas9 enzyme fused to a deaminase enzyme to convert a targeted DNA base pair (e.g., A•T to I•T) without disrupting the DNA backbone. Subsequently, the cell’s repair machinery converts the modified base into a desired substitution. Prime editing is a gene editing technique that allows the precise insertion, deletion, or substitution of DNA sequences at target sites, without requiring DSBs. Prime editors consist of a catalytically impaired Cas9 fused to an engineered reverse transcriptase and a prime editing guide RNA (pegRNA). The pegRNA directs the reverse transcriptase (RT) to introduce the desired edito into the target DNA. PBS: primer binding site, RTT: reverse transcription template.CC BY · PubMed Central
Figure 2 Intravitreal and subretinal nanoparticle delivery for genome editing in the retina. The figure illustrates the targeted delivery of nanoparticles to the retina via intravitreal and subretinal injection techniques. A fundamental challenge is to develop tailored vectors capable of overcoming multiple biological and molecular barriers to efficiently deliver therapeutic agents to target retinal cells in vivo, while minimizing adverse side-effects. The nanoparticles are designed to evade the immune system, enabling efficient and precise transportation of CRISPR-Cas9 cargo to the target cells. Once internalized, nanoparticles must escape endosomes and release their cargo into the cytosol. The nanoparticles carry a diverse payload, including ribonucleoproteins (RNP), mRNA, and DNA, to facilitate genome editing within the retinal cells’ nuclei.
Figure 2 Intravitreal and subretinal nanoparticle delivery for genome editing in the retina. The figure illustrates the targeted delivery of nanoparticles to the retina via intravitreal and subretinal injection techniques. A fundamental challenge is to develop tailored vectors capable of overcoming multiple biological and molecular barriers to efficiently deliver therapeutic agents to target retinal cells in vivo, while minimizing adverse side-effects. The nanoparticles are designed to evade the immune system, enabling efficient and precise transportation of CRISPR-Cas9 cargo to the target cells. Once internalized, nanoparticles must escape endosomes and release their cargo into the cytosol. The nanoparticles carry a diverse payload, including ribonucleoproteins (RNP), mRNA, and DNA, to facilitate genome editing within the retinal cells’ nuclei.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Research works printed but not linked: 1

  1. 2022, Editas medicine announces clinical data demonstrating proof of concept of EDIT-101 from phase 1/2 BRILLIANCE trial [press release]

Cited by

See all 21

Metadata

Authors
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C.
Affiliations
  • Universidade Nova de Lisboa (PT)
  • Champalimaud Foundation (PT)
Corresponding author
  • Antas, Pedro
  • Seabra, Miguel C.
Venue
Frontiers in Ophthalmology
Published
2023-09-19
Volume
3
Pages
1270561-1270561
ISSN
2674-0826 (ISSN-L)
OpenAlex
W4386895570
Cited by
21
References
84
Citations by year
2026: 3 · 2025: 12 · 2024: 6
FWCI
0.55
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Ophthalmology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • Fundação Champalimaud
  • Fundação para a Ciência e a Tecnologia (EXPL/MED-OUT/0599/2021, CEECIND/03862/2020)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
inherited retinal disease, gene therapy, genome editing, CRISPR/Cas9, base editing, prime editing, nanoparticle-mediated gene delivery, ocular gene therapy, blindness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. https://app.cochat.ai/papers/10.3389/fopht.2023.1270561
The paper
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023). Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. Frontiers in Ophthalmology. https://doi.org/10.3389/fopht.2023.1270561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.